What Blood Tests Should You Get on GLP-1 Medications?

You started a GLP-1 medication to change one number on the scale, and it's working — but now you're wondering what's happening everywhere the scale can't see. Is your muscle coming along for the ride down? Are your kidneys handling the weeks when nausea kept you from drinking enough water? Is the cholesterol you've been meaning to deal with actually moving? A GLP-1 like semaglutide or tirzepatide reshapes a lot of your metabolism at once, and most of that story is written in bloodwork you have to go looking for. This guide walks through the biomarkers worth measuring before you start and while you're on treatment, why each one matters, and how to think about timing — so you can bring specific questions to the person who prescribes and manages your therapy.

To be clear up front: a lab result is a data point, not a diagnosis, and nothing here is a substitute for the clinician managing your medication. The goal is to help you measure the right things and understand what they mean.

Why bloodwork matters more on a GLP-1, not less

GLP-1 receptor agonists don't just curb appetite. They slow gastric emptying, shift blood sugar and insulin dynamics, and drive rapid changes in body composition — and each of those has a measurable fingerprint. Two realities make monitoring especially useful.

First, weight loss on these drugs is fast, and not all of it is fat. In the body-composition substudy of the STEP 1 trial, adults on semaglutide lost about 15% of body weight over 68 weeks; roughly a third of the tissue lost was lean body mass rather than fat, with fat mass falling about 19% and lean mass about 10% (Endocrine Society substudy; trial overview). That's expected with any large weight reduction, and lean mass as a share of body weight actually improved — but it's a reason to keep an eye on muscle and nutrition rather than assume the scale tells the whole story.

Second, the most common side effects are gastrointestinal — nausea, vomiting, diarrhea — and during the weeks those symptoms peak, dehydration can put transient strain on the kidneys. The FDA label for semaglutide notes that acute kidney injury has occurred in the setting of GI reactions causing volume depletion, and advises monitoring renal function in people reporting those reactions, "especially during dosage initiation and escalation" (WEGOVY prescribing information). A baseline number gives your clinician something to compare against if a rough stretch comes.

The baseline panel: measure before you start

A pre-treatment snapshot is the single most useful thing you can do, because every later result is only as meaningful as the "before" you can compare it to. Clinicians and lab guides commonly group a baseline around a few organ systems (Choose Health; InsideTracker):

You don't necessarily need every marker on day one, and which ones make sense depends on your history — that's a conversation to have with your prescriber. But a baseline that at least covers glucose, kidney, liver, and lipids gives you a foundation the rest of your monitoring builds on.

What to track while you're on treatment

Blood sugar: A1C and glucose

HbA1c reflects your average blood sugar over roughly three months, which makes it a natural rhythm for re-checking. The American Diabetes Association frames the cadence simply: about every six months when a result is in the target range, and about every three months when medications have changed or the last result was off target (ADA). Starting or adjusting a GLP-1 is exactly the kind of change that argues for the tighter interval, at least early on. GLP-1s tend to push glucose and A1C downward for many people (InsideTracker) — tracking it lets you and your clinician see the trend rather than guess at it.

Kidney function: creatinine and eGFR

This is the marker most tied to how your first weeks actually go. If nausea or diarrhea keeps you from staying hydrated, kidney markers are where that shows up. Because the label specifically flags monitoring renal function during initiation and dose escalation when volume-depleting side effects appear (WEGOVY PI), a baseline creatinine and eGFR — and a re-check if you have a hard stretch — is worth discussing before you titrate up.

Liver enzymes

Many people starting GLP-1 therapy carry some degree of metabolic-associated fatty liver, and ALT is a common window into it. As weight comes down, ALT often falls too (InsideTracker). Tracking ALT, AST, and GGT over time turns a vague sense of "getting healthier" into something you can actually see move.

Lipids and cardiovascular markers

Weight loss frequently improves the lipid picture — GLP-1 use has been associated with lower LDL, total cholesterol, and triglycerides (InsideTracker). If you're watching heart-related risk, an ApoB or a standard lipid panel repeated a few months in shows whether the change on the scale is translating into the numbers that matter more for the long run.

Muscle, protein, and nutrition

This is the part the scale hides. Given how much lean mass can move during rapid loss (STEP 1 substudy), it's reasonable to pay attention to nutrition status and muscle over the course of treatment. Bloodwork can't measure muscle directly, but markers tied to protein intake and nutrition — along with B12, vitamin D, and iron if your food intake has dropped sharply (Choose Health) — round out the picture. Body-composition measurement (like a DEXA scan) is the complementary tool that sees what blood can't.

Inflammation

hs-CRP is a broad marker of systemic inflammation, and it commonly trends downward with GLP-1-associated weight loss (InsideTracker). It won't change your day-to-day, but as a repeated measure it's a useful part of the longevity-and-metabolic story many people on these medications care about.

How often should you re-test?

There's no single schedule, and the right one depends on your history and how you're doing — a decision for you and your clinician, not a template. That said, a common shape looks like this (Choose Health): a full baseline before starting; an earlier check in the first couple of months, when doses are still climbing and side effects are most active; then re-checks roughly every three to six months depending on your situation; plus prompt testing anytime new symptoms show up, such as persistent abdominal pain, unusual fatigue, or changes in urination. The A1C rhythm above is a helpful anchor for the glucose markers specifically.

The point isn't to run every test constantly. It's to measure the right things at the moments they're most informative, and to build a trend line you can actually read.

Turning results into a picture you can use

A GLP-1 changes many systems at once, so the most useful thing bloodwork gives you isn't any single value — it's the pattern across kidney, liver, glucose, lipids, and nutrition over time, read alongside what's happening to your body composition. One number on one day is noise; a trend is signal.

That's the gap Sidewalk is built to close. We help you decide which biomarkers are worth measuring for where you are, track them over time so the trend is legible instead of scattered across lab portals, and connect the picture to a qualified practitioner who can act on it. If you're on a GLP-1 or thinking about starting, the most useful first move is simply to establish your baseline — then keep measuring, so the changes you can't feel don't stay invisible.

This article is for general education and is not medical advice. Lab results don't diagnose or treat any condition, and decisions about starting, stopping, or changing any medication belong with the licensed clinician who manages your care.